Global Leading Market Research Publisher QYResearch announces the release of its latest report “Icodextrin-based Peritoneal Dialysis Solution – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Icodextrin-based Peritoneal Dialysis Solution market, including market size, share, demand, industry development status, and forecasts for the next few years.
For patients with end-stage renal disease (ESRD) undergoing continuous ambulatory peritoneal dialysis (CAPD), conventional glucose-based dialysates are rapidly absorbed during long (8-16 hour) overnight dwells, leading to loss of ultrafiltration (fluid removal), fluid overload, and inadequate solute clearance. The icodextrin-based peritoneal dialysis solution addresses this through glucose polymer technology: icodextrin (a starch-derived glucose polymer) creates a colloid osmotic gradient that sustains ultrafiltration throughout the entire long dwell, unlike glucose which is absorbed within 4-6 hours. According to QYResearch’s updated model, the global market for Icodextrin-based Peritoneal Dialysis Solution was estimated to be worth US$ 89.1 million in 2025 and is projected to reach US$ 153 million, growing at a CAGR of 8.1% from 2026 to 2032. Icodextrin-based peritoneal dialysis solution is a dialysate designed for continuous ambulatory peritoneal dialysis (CAPD) in patients with end-stage renal disease (ESRD), primarily used as a single long-dwell daily exchange with a dwell time of 8 to 16 hours. This formulation is suitable for patients with high-average or high peritoneal transport status, as assessed by the peritoneal equilibration test (PET), providing enhanced long-dwell ultrafiltration and improved creatinine and blood urea nitrogen clearance. Icodextrin-based peritoneal dialysis solution is intended exclusively for intraperitoneal administration and must not be given intravenously or intra-arterially. Treatment regimens should be determined and supervised by physicians experienced in peritoneal dialysis, and proper patient training is recommended to ensure safe and effective use. In 2024, the global sales volume of icodextrin-based peritoneal dialysis solution is projected to reach 6.63 million units, with an average price of USD 12.5 per unit.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097358/icodextrin-based-peritoneal-dialysis-solution
1. Technical Architecture: Mechanism of Action and Clinical Indications
Icodextrin-based PD solution differs fundamentally from conventional glucose-based solutions in its osmotic agent and dwell characteristics:
| Parameter | Icodextrin-Based Solution | Conventional Glucose Solution (2.5%) | Clinical Advantage |
|---|---|---|---|
| Osmotic agent | Icodextrin (glucose polymer, MW 15-45 kDa) | Glucose (MW 180 Da) | Icodextrin: sustained osmotic gradient |
| Dwell time | 8-16 hours (long dwell, typically overnight) | 4-6 hours (short dwell) | Icodextrin enables once-daily exchange |
| Ultrafiltration profile | Sustained (increases over dwell time) | Peaks early, declines after 4-6 hours | Icodextrin: superior fluid removal in long dwell |
| Glucose absorption | Minimal (10-20% of administered) | Complete (80-100% absorbed) | Icodextrin: less glycemic impact |
| Caloric load | Lower (no glucose absorption) | Higher (glucose absorbed) | Icodextrin: better for diabetic patients |
| Indicated PET category | High-average or high transport | All transport categories | Icodextrin specifically for rapid transporters |
| Primary use | Long dwell (overnight) | Short dwell (daytime exchanges) | Complementary to glucose solutions |
Key technical challenge – manufacturing sterility and packaging: Icodextrin solution requires high-temperature sterilization (121°C) without degrading the polymer. Over the past six months, several advancements have emerged:
- Baxter (February 2026) introduced a dual-chamber bag system (icodextrin separated from electrolytes until administration), extending shelf life from 18 to 24 months and reducing glucose degradation products (GDPs) by 70%.
- Vantive (March 2026) commercialized a ready-to-use icodextrin solution with integrated tubing and flow control clamp, reducing patient connection time from 15 minutes to 5 minutes.
- Pharmasyntez Group (January 2026) launched a lower-cost icodextrin formulation targeting emerging markets (Russia, CIS, Eastern Europe), priced 30% below Baxter’s product.
Industry insight – PD patient population and icodextrin adoption:
| Parameter | Global Estimate |
|---|---|
| Total ESRD patients (2024) | 3.5-4.0 million |
| PD patients (2024) | 400,000-500,000 (10-15% of ESRD) |
| High/high-average transporters (PET) | 30-40% of PD patients |
| Icodextrin-eligible patients | 120,000-200,000 |
| Current icodextrin penetration | 50-60% (higher in developed markets) |
2. Market Segmentation: Volume and Application
The Icodextrin-based Peritoneal Dialysis Solution market is segmented as below:
Key Players: Baxter (US), Vantive (US – Baxter spin-off), Pharmasyntez Group (Russia)
Segment by Volume:
- 2L – Largest segment (60% of 2025 units). Standard overnight dwell for most patients.
- 2.5L – 40% of units. Larger patients, higher ultrafiltration requirements.
Segment by Application:
- Hospital – 40% of revenue. Initial prescription, inpatient training, acute complications.
- Clinic – 35% of revenue. Outpatient dialysis centers, follow-up monitoring.
- Dialysis Center – 25% of revenue. Dedicated PD units, high-volume patient populations.
Typical user case – high-transporter PD patient: A 60-year-old diabetic ESRD patient with high peritoneal transport status (PET) experiences fluid overload (edema, hypertension) on conventional glucose-based overnight dwell (glucose absorbed, no ultrafiltration). Switch to icodextrin-based solution (2L, 12.5% concentration) for overnight dwell (10 hours). Results: ultrafiltration increases from 0 mL to 600-800 mL per night, blood pressure improves (reduced antihypertensive medications), and hemoglobin A1c decreases (reduced glucose absorption). Annual cost: icodextrin ($12.50/day × 365 = $4,562) vs. glucose solution ($8/day × 365 = $2,920). Incremental cost: $1,642. Value: reduced hospitalizations for fluid overload (saving $5,000-10,000 annually), improved quality of life.
Exclusive observation – “icodextrin as standard of care”: Clinical guidelines (ISPD, KDIGO) recommend icodextrin for long dwell in high/high-average transport patients to maintain ultrafiltration and prevent fluid overload. Adoption is 80-90% in North America and Western Europe, but only 20-30% in Asia-Pacific and Latin America (cost constraints). Price sensitivity in emerging markets drives demand for lower-cost alternatives (Pharmasyntez).
3. Regional Dynamics and ESRD Prevalence
| Region | Market Share (2025) | Key Drivers |
|---|---|---|
| North America | 40% | Highest PD adoption (home dialysis preference), Baxter/Vantive leadership, strong reimbursement |
| Europe | 30% | Established PD infrastructure (UK, Germany, France, Italy), clinical guideline adherence |
| Asia-Pacific | 20% | Fastest-growing (10% CAGR), China (largest ESRD population, 1.5M+ patients), India, Japan |
| RoW | 10% | Emerging markets (Russia – Pharmasyntez, Latin America, Middle East) |
Exclusive observation – “home dialysis” expansion: PD is a home-based therapy (vs. in-center hemodialysis). Icodextrin’s once-daily long dwell simplifies PD regimens (one icodextrin exchange + 2-3 glucose exchanges), improving patient convenience and adherence. Post-COVID, home dialysis adoption increased 15-20% (infection avoidance). Icodextrin market benefits from home dialysis growth.
4. Competitive Landscape and Outlook
| Supplier | Key Strengths | Focus |
|---|---|---|
| Baxter (US) | Market leader (60%+ share), global distribution, extensive clinical evidence (10+ RCTs), premium pricing | North America, Europe, Asia-Pacific |
| Vantive (US) | Baxter spin-off (2024), focused on renal therapies, dual-chamber bag technology | North America, Europe |
| Pharmasyntez Group (Russia) | Cost leadership (30% below Baxter), emerging markets | Russia, CIS, Eastern Europe |
Technology roadmap (2027-2030):
- Lower-cost icodextrin manufacturing – Enzymatic production processes reducing cost by 20-30%, enabling wider access in emerging markets.
- Biocompatible icodextrin formulations – Neutral pH, low GDP (glucose degradation product) solutions preserving peritoneal membrane function, extending PD technique survival.
- Automated PD (APD)-compatible icodextrin – Optimized for cycler-based overnight PD (vs. CAPD), with improved flow characteristics. Pilot stage.
With 8.1% CAGR and 6.63 million units sold in 2024, the icodextrin-based peritoneal dialysis solution market benefits from ESRD prevalence (growing 5-7% annually due to diabetes, hypertension), home dialysis preference, and clinical guideline recommendations. Key growth drivers: aging population (65+ at highest ESRD risk), diabetic kidney disease epidemic, and fluid overload management in PD patients. Risks include reimbursement pressure (Medicare, private insurers), competition from expanded glucose solution regimens (multiple short dwells), and peritoneal membrane failure (long-term PD complications).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
